Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18857496 | 0.72 | CA12 (0.46) | KDM4EALDH1A1GLAGAACA12 | |
| SCHEMBL18857759 | 0.69 | ECE1 (0.34) | CA12CA1CA2CA9CA14 | |
| SCHEMBL18857760 | 0.68 | KDM4C (0.34) | CA12CA1CA2CA9CA14 | |
| SCHEMBL18854020 | 0.66 | CA12 (0.41) | KDM4EALDH1A1GLAGAACA12 | |
| SCHEMBL18465038 | 0.63 | CA12 (0.41) | KDM4EALDH1A1GLAGAACA12 | |
| SCHEMBL18857752 | 0.62 | ECE1 (0.34) | CA12CA1CA2CA9CA14 | |
| SCHEMBL18857757 | 0.61 | KDM4C (0.36) | — | |
| SCHEMBL9426430 | 0.60 | KDM4E (0.50) | KDM4EALDH1A1GLAGAA | |
| SCHEMBL18857498 | 0.60 | GAA (0.42) | KDM4EALDH1A1GLAGAACA12 | |
| SCHEMBL18426894 | 0.59 | PTGS1 (0.59) | KDM4EALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018093974-A1 | AMINOPYRIDINE BASED BUFFERS WITH WIDE BUFFERING RANGES, ANTIBIOTICS AND MYELIN DISEASE THERAPY | DALY THOMAS (US) | 2018-05-24 | — | — | WO | disclosed |